Profile data is unavailable for this security.
About the company
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
- Revenue in USD (TTM)194.45m
- Net income in USD-26.41m
- Incorporated2017
- Employees188.00
- LocationAvadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
- Phone+353 19015201
- Fax+353 15261077
- Websitehttps://www.avadel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Zevra Therapeutics Inc | 40.59m | -91.99m | 692.24m | 59.00 | -- | 16.87 | -- | 17.06 | -1.90 | -1.90 | 0.823 | 0.7503 | 0.2506 | -- | 3.88 | 687,932.20 | -56.78 | -37.95 | -68.88 | -48.83 | 84.42 | -- | -226.64 | -193.51 | 2.93 | -10.59 | 0.5943 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Nika Pharmaceuticals Inc | 160.00 | -88.57k | 708.22m | -- | -- | -- | -- | 4,426,376.00 | -0.00008 | -0.00008 | 0.00 | -0.0002 | 0.0042 | -- | -- | -- | -231.68 | -21,428.06 | -- | -- | -- | -- | -55,356.25 | -- | -- | -- | 7.69 | -- | -- | -- | -47.74 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 56.04m | -146.78m | 708.76m | 165.00 | -- | 2.38 | -- | 12.65 | -2.41 | -2.41 | 0.9262 | 4.34 | 0.162 | 1.18 | 32.42 | 339,648.50 | -42.43 | -35.88 | -49.96 | -42.05 | 93.29 | 84.82 | -261.91 | -201.78 | 7.79 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| ASP Isotopes Inc | 4.41m | -36.61m | 736.84m | 136.00 | -- | 16.36 | -- | 167.26 | -0.6144 | -0.6144 | 0.0712 | 0.5899 | 0.0647 | -- | 8.42 | 32,393.31 | -49.79 | -- | -58.98 | -- | 37.40 | -- | -769.93 | -- | 7.17 | -5.24 | 0.4493 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| CorMedix Inc | 82.55m | 17.18m | 822.67m | 64.00 | 49.13 | 6.52 | 46.66 | 9.97 | 0.2253 | 0.2253 | 1.34 | 1.70 | 0.7587 | 0.8093 | -- | 1,289,904.00 | 15.79 | -42.85 | 19.78 | -49.82 | 95.19 | 91.93 | 20.81 | -327.99 | 3.99 | -- | 0.00 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Xeris Biopharma Holdings Inc | 222.55m | -45.08m | 837.61m | 394.00 | -- | -- | -- | 3.76 | -0.3015 | -0.3015 | 1.49 | -0.2252 | 0.6826 | 0.8462 | 5.32 | 564,850.30 | -13.83 | -31.61 | -18.63 | -42.28 | 82.21 | 79.76 | -20.25 | -77.77 | 1.17 | -0.8589 | 1.18 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Akebia Therapeutics Inc | 184.91m | -45.31m | 1.02bn | 181.00 | -- | 41.30 | -- | 5.51 | -0.2151 | -0.2151 | 0.8401 | 0.094 | 0.6904 | 1.40 | 4.19 | 1,021,597.00 | -16.92 | -38.92 | -23.98 | -61.07 | 82.92 | 71.93 | -24.51 | -76.49 | 2.02 | -0.7769 | 0.6542 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Amphastar Pharmaceuticals Inc | 730.66m | 141.63m | 1.02bn | 2.03k | 7.88 | 1.38 | 5.11 | 1.40 | 2.76 | 2.76 | 14.25 | 15.76 | 0.4566 | 2.40 | 5.17 | 360,285.50 | 8.85 | 9.84 | 10.31 | 11.71 | 50.50 | 49.55 | 19.38 | 17.15 | 2.02 | 10.89 | 0.4457 | 0.00 | 13.59 | 17.82 | 15.98 | 26.66 | -0.2486 | -- |
| Pacira Biosciences Inc | 702.77m | -103.73m | 1.03bn | 790.00 | -- | 1.29 | -- | 1.47 | -2.25 | -2.25 | 15.19 | 17.25 | 0.4434 | 1.36 | 6.81 | 889,584.80 | -6.54 | 1.87 | -7.51 | 2.22 | 77.61 | 73.06 | -14.76 | 4.84 | 1.99 | -- | 0.4222 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Collegium Pharmaceutical Inc | 664.28m | 43.89m | 1.04bn | 357.00 | 26.66 | 4.42 | 4.43 | 1.56 | 1.21 | 1.21 | 17.27 | 7.30 | 0.4839 | 8.21 | 3.29 | 1,860,737.00 | 3.20 | 4.11 | 4.84 | 6.64 | 57.69 | 55.50 | 6.61 | 8.48 | 1.01 | 2.55 | 0.7813 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 194.45m | -26.41m | 1.05bn | 188.00 | -- | 14.14 | -- | 5.40 | -0.2743 | -0.2743 | 2.02 | 0.7665 | 1.16 | 1.20 | 6.05 | 1,034,309.00 | -15.73 | -42.00 | -22.28 | -50.53 | 90.06 | -- | -13.58 | -194.15 | 2.33 | -1.85 | 0.00 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| Phibro Animal Health Corp | 1.19bn | 31.79m | 1.21bn | 1.94k | 38.04 | 4.53 | 16.24 | 1.01 | 0.7816 | 0.7816 | 29.30 | 6.56 | 1.04 | 2.21 | 6.64 | 613,753.60 | 2.77 | 3.93 | 3.45 | 4.90 | 32.27 | 31.18 | 2.67 | 3.77 | 1.23 | 2.78 | 0.7322 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Innoviva Inc | 369.84m | -59.72m | 1.25bn | 127.00 | -- | 1.93 | -- | 3.37 | -1.06 | -1.06 | 5.00 | 10.31 | 0.2933 | 0.8736 | 4.80 | 2,912,158.00 | -4.74 | 20.06 | -5.29 | 22.10 | 90.68 | -- | -16.15 | 62.81 | 2.30 | 0.8073 | 0.4097 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
| Liquidia Corp | 14.14m | -127.83m | 1.25bn | 157.00 | -- | 25.05 | -- | 88.24 | -1.56 | -1.56 | 0.1743 | 0.5828 | 0.0666 | 2.44 | 7.41 | 90,089.17 | -60.22 | -58.31 | -74.73 | -66.89 | 58.08 | 75.60 | -903.80 | -564.24 | 2.91 | -17.94 | 0.7391 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Harrow Inc | 212.86m | -21.70m | 1.33bn | 382.00 | -- | 22.83 | -- | 6.23 | -0.607 | -0.607 | 5.96 | 1.58 | 0.6453 | 5.04 | 4.02 | 557,219.90 | -6.58 | -9.11 | -10.05 | -10.89 | 74.53 | 72.78 | -10.19 | -14.34 | 0.8494 | 0.1846 | 0.7974 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
Data as of Jul 18 2025. Currency figures normalised to Avadel Pharmaceuticals PLC's reporting currency: US Dollar USD
51.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Mar 2025 | 13.54m | 14.05% |
| Tontine Associates LLCas of 31 Mar 2025 | 6.13m | 6.36% |
| Brandes Investment Partners LPas of 31 Mar 2025 | 5.67m | 5.88% |
| Two Seas Capital LPas of 31 Mar 2025 | 4.95m | 5.13% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 4.69m | 4.87% |
| Polar Capital LLPas of 31 Mar 2025 | 4.36m | 4.52% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 3.74m | 3.88% |
| Wealth Effects LLCas of 31 Mar 2025 | 2.37m | 2.46% |
| Tang Capital Management LLCas of 31 Mar 2025 | 2.10m | 2.18% |
| Citadel Advisors LLCas of 31 Mar 2025 | 1.93m | 2.01% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
